BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Olmo-García MI, Muros MA, López-de-la-Torre M, Agudelo M, Bello P, Soriano JM, Merino-Torres JF. Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal. J Clin Med 2020;9:E2203. [PMID: 32664679 DOI: 10.3390/jcm9072203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Prado-Wohlwend S, Bernal-Vergara JC, Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M, Bello-Arques P; Endocrinology Working Group of the SEMNIM. Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021:S2253-8089(21)00164-6. [PMID: 34920969 DOI: 10.1016/j.remnie.2021.11.001] [Reference Citation Analysis]
3 Huot Daneault A, Desaulniers M, Beauregard JM, Beaulieu A, Arsenault F, April G, Turcotte É, Buteau FA. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report. Front Endocrinol (Lausanne) 2021;12:705271. [PMID: 34367072 DOI: 10.3389/fendo.2021.705271] [Reference Citation Analysis]
4 Panzuto F. Clinical Challenges in the Management of Neuroendocrine Tumors. J Clin Med 2021;10:E257. [PMID: 33445572 DOI: 10.3390/jcm10020257] [Reference Citation Analysis]
5 Bardasi C, Benatti S, Luppi G, Garajovà I, Piacentini F, Dominici M, Gelsomino F. Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency. Cancers 2022;14:662. [DOI: 10.3390/cancers14030662] [Reference Citation Analysis]